

<b>Clinical factors</b>		<b>Results</b>
<b>Median Age, yr (Range) N=297</b>		70.4 (34.6-93.4)
<b>Gender (%) N=297</b>		
	Female	161 (54.2)
	Male	136 (45.8)
<b>Disease stage (%) N=297</b>		
	IA	131 (44.1)
	IB	96 (32.3)
	2A	47 (15.8)
	2B	23 (7.8)
<b>Histology (%) N=297</b>		
	Adenocarcinoma	187 (63.0)
	Squamous cell carcinoma	84 (28.3)
	Large cell carcinoma	10 (3.4)
	BAC*	9 (3.0)
	NSCLC-NOS**	7 (2.3)
<b>Smoking status (%) N=283</b>		
	Smokers	262 (92.6)
	Never smokers	21 (7.4)
<b>Median pack/year (Range) N=141</b>		50 (6-200)
<b>How Chemotherapy Delivered (%) N=42</b>		
	Neoadjuvant	1 (2.4)
	Adjuvant	35 (83.3)
	Concurrent with radiation	6 (14.3)
<b>Type of Chemotherapy Delivered (%) N=42</b>		
	Carboplatin-based regimen	13 (31.0)
	Cisplatin-based regimen	5 (11.9)
	Other	24 (57.1)
<b>Radiation therapy (%) N=38</b>		
	Definitive radiation	29 (76.3)
	Adjuvant radiation	9 (23.7)
<b>Outcome &amp; Mutational Statistics</b>		
<b>Median Overall Survival, in months (range) N=296</b>		38.8 (0.4-110.5)
<b>Disease recurrence? N=270</b>		
	No	145 (53.7)
	Yes	125 (46.3)
<b>Median Relapse-free Survival, in months (range) N=270</b>		31.7 (0.4-110.5)
<b>Immunohistochemistry (% positive)</b>		
	STAT3 N = 245	229 (93.5)
	p-STAT3 <sup>Y705</sup> N=245	53 (21.6)
	Jak2 N= 245	194 (79.2)
<b>Mutational status (%) N = 270</b>		
	K-Ras mutation, exon 1 codons 12 and 13	70 (26.0)
	EGFR mutation, exon 19	15 (5.6)
*BAC: bronchoalveolar carcinoma		
**NOS: non-otherwise specified		

**Supplemental Table S3. Patient disease characteristics and outcome statistics.**

Key clinical, histological and treatment features, as well as outcome statistics, of the patient population represented on our tissue microarray are indicated. Mutational status for KRAS and EGFR are also shown for this population.